{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T19:55:35Z","timestamp":1778356535840,"version":"3.51.4"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2010,11,10]],"date-time":"2010-11-10T00:00:00Z","timestamp":1289347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,11,10]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>This open-label multi-centre study evaluated a new intravenous immunoglobulin, Gammaplex\u00ae, in the treatment of 50 patients with primary immunodeficiency and significant hypogammglobulinaemia. Patients treated previously with other intravenous immunoglobulins received Gammaplex\u00ae on their same infusion schedule for 1 year; 22 were on a 21-day and 28 on a 28-day regimen (300\u2013800 mg\/kg\/infusion). There were no serious, acute bacterial infections, whereas six subjects (12\u00b70%) had at least one such infection in the 6 months before enrolment. Forty subjects (80\u00b70%) had at least one non-serious infection; the median number of infective episodes per subject per year was 3\u00b707. Antibiotics were taken by 38 subjects therapeutically and prophylactically by 16 at some time. Fewer than half (46\u00b70%) missed any time off work or school because of infection or other illness. Trough immunoglobulin (Ig)G levels were above 6\u00b700 g\/l in all subjects at all assessments after 15 weeks with two exceptions. Overall, 21\u00b72% of infusions were associated with an adverse event up to 72 h after infusion. The frequency of adverse events increased with infusion rate. Headache was the most common product-related adverse event (7\u00b75% of 703 infusions). In conclusion, Gammaplex\u00ae is effective in primary immunodeficiency and is well tolerated.<\/jats:p>","DOI":"10.1111\/j.1365-2249.2010.04247.x","type":"journal-article","created":{"date-parts":[[2010,11,10]],"date-time":"2010-11-10T15:55:47Z","timestamp":1289404547000},"page":"510-515","source":"Crossref","is-referenced-by-count":20,"title":["Efficacy and safety of a new immunoglobulin G product, Gammaplex\u00ae, in primary immunodeficiency diseases"],"prefix":"10.1093","volume":"162","author":[{"given":"J N","family":"Moy","sequence":"first","affiliation":[{"name":"Rush University Medical Center, Chicago, IL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A M","family":"Scharenberg","sequence":"additional","affiliation":[{"name":"University of WA School of Medicine and Seattle Children's Research Institute, Department of Paediatrics, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M R","family":"Stein","sequence":"additional","affiliation":[{"name":"Allergy Associates of the Palm Beaches, North Palm Beach, FL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Suez","sequence":"additional","affiliation":[{"name":"Allergy, Asthma and Immunology Clinic, Irving, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R L","family":"Roberts","sequence":"additional","affiliation":[{"name":"UCLA Medical Center, Los Angeles, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R J","family":"Levy","sequence":"additional","affiliation":[{"name":"Family Allergy and Asthma Center, Atlanta, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Ballow","sequence":"additional","affiliation":[{"name":"Children's Hospital at Buffalo Allergy Division, Buffalo, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M B","family":"Fasano","sequence":"additional","affiliation":[{"name":"University of Iowa Carver College of Medicine, Division of Allergy\/Immunology, Iowa City, IA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C H","family":"Dash","sequence":"additional","affiliation":[{"name":"Bio Products Laboratory, Dagger Lane, Elstree, Hertfordshire, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S J","family":"Leach","sequence":"additional","affiliation":[{"name":"Bio Products Laboratory, Dagger Lane, Elstree, Hertfordshire, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2010,11,10]]},"reference":[{"key":"2021122708483930400_b1","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1365-2249.2007.03432.x","article-title":"Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review","volume":"149","author":"Wood","year":"2007","journal-title":"Clin Exp Immunol"},{"key":"2021122708483930400_b2","first-page":"335","article-title":"High- vs. low-dose immunoglobulin therapy in the long-term treatment of X-linked agammaglobulinemia","volume":"146","author":"Liese","year":"1992","journal-title":"Am J Dis Child"},{"key":"2021122708483930400_b3","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0002-9343(85)90006-3","article-title":"Benefit of intravenous IgG replacement in hypogammaglobulinemic patients with chronic sinopulmonary disease","volume":"79","author":"Roifman","year":"1985","journal-title":"Am J Med"},{"key":"2021122708483930400_b4","doi-asserted-by":"crossref","first-page":"435","DOI":"10.7326\/0003-4819-101-4-435","article-title":"Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease","volume":"101","author":"Cunningham-Rundles","year":"1984","journal-title":"Ann Intern Med"},{"key":"2021122708483930400_b5","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1345\/aph.1E040","article-title":"Acute renal failure and intravenous immune globulin: occurs with sucrose-stabilized, but not with d-sorbitol-stabilzed, formulation","volume":"38","author":"Chapman","year":"2004","journal-title":"Ann Pharmacother"},{"key":"2021122708483930400_b6","volume-title":"Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency","author":"US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research","year":"2005"},{"key":"2021122708483930400_b7","volume-title":"Note for guidance on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIG)","author":"Committee for Proprietary Medicinal Products","year":"2000"},{"key":"2021122708483930400_b8","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s11882-002-0069-z","article-title":"A history of immune globulin therapy, from the Harvard Crash Program to monoclonal antibodies","volume":"2","author":"Berger","year":"2002","journal-title":"Curr Allergy Asthma Rep"},{"key":"2021122708483930400_b9","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(87)90494-6","article-title":"High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease","volume":"1","author":"Roifman","year":"1987","journal-title":"Lancet"},{"key":"2021122708483930400_b10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.7326\/0003-4819-135-3-200108070-00008","article-title":"The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia: a randomized double-blind, multicenter crossover trial","volume":"135","author":"Eijkhout","year":"2001","journal-title":"Ann Intern Med"},{"key":"2021122708483930400_b11","first-page":"77","article-title":"Survival of IgG subclasses following administration of intravenous gammaglobulin in patients with primary immunodeficiency diseases","volume-title":"Clinical use of intravenous immunoglobulins","author":"Ochs","year":"1986"},{"key":"2021122708483930400_b12","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s10875-006-9025-3","article-title":"Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IVIG 10%] in patients with primary immunodeficiency","volume":"26","author":"Church","year":"2006","journal-title":"J Clin Immunol"},{"key":"2021122708483930400_b13","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10875-008-9231-2","article-title":"Safety and efficacy of Privigen\u00ae, a novel 10% liquid immunoglobulin preparation for intravenous use, in patients with primary immunodeficiencies","volume":"29","author":"Stein","year":"2009","journal-title":"J Clin Immunol"},{"key":"2021122708483930400_b14","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1023\/B:JOCI.0000029108.18995.61","article-title":"Safety, efficacy and pharmacokinetics of Flebogamma\u00ae 5% [Immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases","volume":"24","author":"Berger","year":"2004","journal-title":"J Clin Immunol"},{"key":"2021122708483930400_b15","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1023\/B:JOCI.0000025453.23817.3f","article-title":"Octagam\u00ae 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases","volume":"24","author":"Ochs","year":"2004","journal-title":"J Clin Immunol"},{"key":"2021122708483930400_b16","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1046\/j.1423-0410.2003.00278.x","article-title":"Pharmacokinetics of total immunoglobulin and immunoglobulin G subclasses in patients undergoing replacement therapy for primary immunodeficiency disorders","volume":"84","author":"Alyanakian","year":"2003","journal-title":"Vox Sang"},{"key":"2021122708483930400_b17","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1046\/j.1423-0410.2003.00286.x","article-title":"Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex\u2122, 10%)","volume":"84","author":"Ballow","year":"2003","journal-title":"Vox Sang"},{"key":"2021122708483930400_b18","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1212\/01.WNL.0000074394.15882.83","article-title":"Strokes, thromboembolic events and IVIg. Rare incidents blemish an excellent safety record","volume":"60","author":"Dalakas","year":"2003","journal-title":"Neurology"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2249.2010.04247.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/162\/3\/510\/41924398\/j.1365-2249.2010.04247.x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/162\/3\/510\/41924398\/j.1365-2249.2010.04247.x.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T16:18:12Z","timestamp":1641053892000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/162\/3\/510\/6438618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,10]]},"references-count":18,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2010,11,10]]},"published-print":{"date-parts":[[2010,11,10]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2249.2010.04247.x","relation":{},"ISSN":["1365-2249","0009-9104"],"issn-type":[{"value":"1365-2249","type":"electronic"},{"value":"0009-9104","type":"print"}],"subject":[],"published-other":{"date-parts":[[2010,12]]},"published":{"date-parts":[[2010,11,10]]}}}